Remove Myocardial Infarction Remove Obesity Remove Risk Factors
article thumbnail

Adherence to optimal medical therapy and control of cardiovascular risk factors in patients after ST elevation myocardial infarction in Mexico

Frontiers in Cardiovascular Medicine

IntroductionIn developing countries, there is a notable scarcity of real-world data on adherence to optimal medical therapy (OMT) and its correlation with major cardiovascular adverse events (MACEs) after ST-elevation myocardial infarction (STEMI). Strategies to improve adherence to OMT and risk factor control are needed.

article thumbnail

Research Data from Minneapolis Heart Institute Foundation at ACC 2024 Reveal Trends in Cardiovascular Risk Factors and Preventive Medication Use Prior to Heart Attacks

DAIC

The Minneapolis Heart Institute Foundation (MHIF) is presenting leading research focused on trends in ST-elevation myocardial infarction (STEMI), the most severe form of a heart attack, at the American College of Cardiology’s Annual Scientific Session (ACC.24), 24), being held April 6-8 in Atltanta, GA.

article thumbnail

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Cardiometabolic Health Congress

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52
article thumbnail

Five Things Every Middle Aged Adult Should Know About Sleep & Heart Disease.

Dr. Paddy Barrett

As we get older, the risk of dementia increases for everyone, regardless of risk factor control. Poor Sleep Is A Major Risk Factor For Insulin Resistance. Insulin resistance is a significant driver of cardiovascular risk. Obesity is one of the biggest global health concerns we face today.

article thumbnail

7 Things You Can Do To Reduce Your Risk Even If You Already Have Heart Disease.

Dr. Paddy Barrett

Primordial prevention is changing the environment around you so you do not develop the risk factors for heart disease and, by extension, do not get the disease early in life. New obesity medications such as GLP-1 agonists have shown significant reductions in weight in those with a prior heart attack. J Am Heart Assoc.

article thumbnail

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

ET Main Tent (Hall B1) - A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients with HFrEF and HFpEF: Principal Results From the RELIEVE-HF Trial - Empagliflozin After Acute Myocardial Infarction: Results of the EMPACT-MI Trial - CSL112 (Apolipoprotein A-I) Infusions and Cardiovascular Outcomes in Patients (..)

article thumbnail

Atherosclerosis Updates from the 92nd EAS Congress

Cardiometabolic Health Congress

In this late-breaking session, Dr. Jorge Plutzky (United States of America) presented the SELECT study, demonstrating semaglutide’s cardiovascular benefits in overweight/obese patients with CVD but without T2D. Higher baseline hsCRP levels correlated with increased risks of MI, CVD death, and all-cause death. Dr. Jeanine E.